Market Snapshot

S&P Futures
4,195.00
Dow Futures
34,442.00
NASDAQ Futures
13,603.00

8.75$0.03 0.34%
At close    04:00 PM   
From: To:

Stock Snapshot

8.72
Prev. Close
8.63
Open
361.38M
Market Cap
3.26M
Number of Shares
8.50
Day Low
8.81
Day High
8.75
-
P/E Ratio
32.70M
Free Float in %
-3.31
EPS 2021
6.59
Book Value per Share
6.29
Cash Flow per Share
AVROBIO, Inc. (AVRO)
AVROBIO, Inc. (AVRO) stock rallied over 0.34% intraday to trade at $8.75 per share on NASDAQ. The stock opened with a fall of -1.03% at $8.63 and touched an intraday high of $8.81, rising 1.03% against the last close of $8.72. The stock went to a low of $8.50 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-05-06$8.63$8.75$8.75$8.81$8.50564,295
2021-05-05$9.15$8.72$8.72$9.15$8.71573,700
2021-05-04$9.62$8.98$8.98$9.72$8.72830,400
2021-05-03$11.48$9.48$9.48$11.50$9.28837,900
2021-04-30$11.53$11.68$11.68$11.80$11.46173,600
2021-04-29$11.56$11.59$11.59$11.72$11.22163,300
2021-04-28$11.80$11.51$11.51$11.99$11.32215,200
2021-04-27$11.87$11.61$11.61$12.01$11.50174,200
2021-04-26$11.33$11.80$11.80$11.93$11.29208,800
2021-04-23$11.54$11.34$11.34$11.64$11.21201,400
2021-04-22$11.13$11.33$11.33$11.76$10.77261,000
AVROBIO, Inc.
Building 300
Suite 201 One Kendall Square
Cambridge, MA 02139
United States

http://www.avrobio.com
617 914 8420
Employees
121
Sector
Healthcare
Sales or Revenue
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30
Mr. Geoff MacKay
Co- Founder, Pres, CEO & Director
Mr. Erik Ostrowski M.B.A.
CFO & Treasurer
Mr. Steven N. Avruch J.D.
Chief Legal Officer & Sec.
AVROBIO, Inc.
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.